Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

Abstract Introduction The majority of metastatic renal cell carcinoma (mRCC) patients receive one or more VEGFR TKI agents, alone or in combination with an immune-oncology (IO) agent or an mTOR inhibitor. To date, the cost of adverse events (AEs) common to VEGFR TKIs has not been quantified. This st...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, Vijay Kasturi, Thomas E. Hutson
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-10-01
Col·lecció:	BMC Health Services Research
Matèries:	Metastatic renal cell carcinoma VEGFR tyrosine kinase inhibitor (TKI) Adverse event Claims analysis Third-line treatment Cost of care
Accés en línia:	https://doi.org/10.1186/s12913-024-11587-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!